Literature DB >> 11557908

Pharmacodynamic modeling of time-dependent transduction systems.

D E Mager1, W J Jusko.   

Abstract

Mesh：

Year:  2001        PMID： 11557908     DOI： 10.1067/mcp.2001.118244

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  56 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

3.  Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding.

Authors:  Michael Weiss; Wonku Kang
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

4.  Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

Authors:  Dongyang Liu; Hoi-Kei Lon; Debra C Dubois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-16       Impact factor: 2.745

5.  Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.

Authors:  Ronald A Siegel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-12-12       Impact factor: 2.745

Review 6.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

7.  Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.

Authors:  Evelyn D Lobo; Joseph P Balthasar
Journal:  AAPS PharmSci       Date:  2002

8.  Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.

Authors:  Qiong Wu; Meng-yao Li; Han-qing Li; Chen-hui Deng; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2013-10-07       Impact factor: 6.150

9.  Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Bonnie H Hylander; Elizabeth A Repasky; Wen W Ma; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-03       Impact factor: 3.333

10.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.